Submission FAQs

What is the submission deadline?

The deadline for submitting late breaker abstracts is 15 January 2024 at midnight GMT.

How do I access the abstract submission site?

https://worldhepatitissummit.org/abstracts/

What language can I submit the abstracts in?

Abstracts should be in English only.

When will I know if my submission has been accepted?

Authors will be notified whether their submission has been accepted or rejected w/c 22 January 2024.

Is there a character limit for my abstract?

Abstracts should not exceed 3000 characters.

What are the guidelines for including images?

Each abstract is allowed to include a maximum of two uploaded file – these could either be tables, charts, graphics or images / photos – but this is not a requirement.

How should my abstract content be formatted?

Content should be structured into the following five sections:

  • Background
  • Objectives
  • Methods
  • Results / Outcomes
  • Conclusions / Lessons learnt 

How will my submission be presented at the summit?

A select number of submissions will be accepted to give oral presentations. All other submissions that meet requirements will be accepted for posters.

Where and when will the posters be displayed?

Posters will be displayed at Culturgest, Lisbon, from 9 – 11 April 2024.

Which category should I submit under?

Please select the category that most closely aligns to your work.

The submission review panel will have the authority to reassign submissions to the most appropriate category.

Can I submit my abstract under more than one submission category?

No, you will be able to submit against one category per submission.

May I submit more than one abstract?

Yes. There is no limit to the number of abstracts you can submit. You must complete one online application form for each submission. You cannot submit the same abstract in different categories.

Is there a submission fee?

No. There are no fees associated to making a submission but if an abstract is accepted either as an oral or poster, the submitter needs to have a valid registration in order for it to be included in the summit.

What are the registration fees for WHS 2024?

Registration is now open! Find out registration fees here

Is the presence mandatory for participants who will present a poster?

Yes. We strongly encourage you to attend in-person.

If an abstract is accepted for an oral presentation will there be instructions available to presenters?

Yes. Detailed instructions will be made available closer to the summit.

If my abstract is accepted, can I choose whether to attend virtually or in person?

We strongly encourage you to attend in-person.

Are scholarships available for abstract presenters?

Unfortunately, there will be no scholarships available for late breaker abstract presenters. Scholarships were awarded to the top rating abstracts from low and middle income countries who submitted in the earlier window. 

Whom do I contact with additional questions?

Please view the Guidelines for Abstract Submissions or email: WHS@serenevents.com  

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

The role of decentralised and community-led services in accelerating progress towards elimination.

Role of harm reduction.